Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920

Rhea-AI Summary

Tevogen Bio (Nasdaq: TVGN) has partnered with Microsoft to advance its oncology treatment pipeline through AI-driven target identification for Human Papilloma Virus (HPV). The company is developing TVGN 920, its first oncology product, using its proprietary ExacTcell™ technology to create HPV-specific cytotoxic T cell (CTL) treatments. The technology, previously successful with SARS-CoV-2-specific CTLs, is being adapted for HPV treatment, targeting a condition that affects 5.5 million women annually, with 200,000 diagnosed with high-grade dysplasia. Tevogen.AI utilizes Microsoft's advanced tools to analyze HPV genome proteins and identify potential CTL targets for clinical trials.

Positive

• Partnership with Microsoft for AI-driven target identification
• Advancement of first oncology product TVGN 920
• Proven ExacTcell™ technology platform with previous success in SARS-CoV-2
• Large addressable market of 5.5 million women annually

Negative

• Pre-clinical stage product with no proven efficacy yet
• Early-stage development with uncertain timeline to market

Insights

Medical Research Analyst

This pre-clinical development announcement for TVGN 920 marks Tevogen Bio's strategic entry into HPV-targeted immunotherapy. The collaboration with Microsoft's AI capabilities could significantly accelerate target identification and development timelines. The market opportunity is substantial, with 5.5 million women annually affected by HPV 16/18 and 200,000 annual cases of high-grade dysplasia.

The ExacTcell™ platform's demonstrated success with SARS-CoV-2 CTLs provides technical validation for this HPV application. However, investors should note that this is still in early pre-clinical stages, with significant development milestones ahead before potential commercialization. The AI-driven approach to target identification could reduce development costs and timeline risks compared to traditional methods.

Tech Expert

The Microsoft partnership brings substantial technological advantages to Tevogen's development process. The integration of machine learning for protein analysis and target identification represents a significant competitive edge in the immunotherapy space. The automation of critical development steps through AI could potentially reduce both time and costs in the pre-clinical phase.

The creation of a comprehensive HPV genome protein dataset, combined with Microsoft's advanced AI tools, positions Tevogen to potentially identify optimal CTL targets more efficiently than traditional methods. This tech-forward approach could become a valuable asset for future pipeline expansions beyond HPV.

• Tevogen Bio begins pre-clinical effort for TVGN 920, signaling the start of its oncology treatment pipeline.
• Tevogen Bio created a data set containing known proteins in the HPV genome to identify targets, accelerating the pre-clinical process.
• 5.5 million women per year have HPV 16/18; of these 200,000 women per year are diagnosed with high grade dysplasia.

WARREN, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, recently announced its Artificial Intelligence effort, Tevogen.AI, had partnered with Microsoft (Nasdaq: MSFT), the world’s leading AI company.

Using Microsoft’s suite of advanced tools, Tevogen Bio is proactively investigating potential treatments for HPV to create a portfolio of oncology products. The company has developed a dataset of proteins from the HPV genome and is identifying cytotoxic T cell (CTL) targets to choose for a clinical trial for TVGN 920, its first oncology product. Through Tevogen’s proprietary ExacTcell™ technology, where CTLs are trained to detect specific targets and then expanded, the company aims to be prepared to deliver an HPV-specific CTL treatment.

“Our ExacTcell technology, which has proven effective in developing SARS-CoV-2-specific CTLs, can be rapidly adapted to create CTL products targeting a wide range of viruses, including HPV,” said Dr. Neal Flomenberg, Chief Scientific Officer at Tevogen Bio. “While the specific targets may vary between viruses, the platform itself is well-established, enabling a swift response to emerging infectious threats.”

“By leveraging Microsoft’s cutting-edge AI and cloud technologies, we’re able to accelerate our target identification and pre-clinical processes in ways that weren’t previously possible,” said Mittul Mehta, Chief Information Officer and Head of Tevogen.AI. “Our partnership is allowing us to automate critical steps in the development pipeline, enhancing our readiness to quickly address additional indications, such as HPV.”

"With national healthcare cost and patient affordability at the forefront of our presidential candidates’ agendas, the urgency is clear,” commented Ryan Saadi, Founder and CEO, Tevogen Bio. “In 2023, U.S. healthcare spending reached an astounding $4.8 trillion - 17.6% of GDP - highlighting the potential impact on economic prosperity. As the new administration charts its course, Tevogen looks forward to being part of a sustainable solution."

About Tevogen Bio

Tevogen is a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, aiming to address the significant unmet needs of large patient populations. Tevogen leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents and numerous pending patents, two of which are related to artificial intelligence.

Tevogen is driven by a team of experienced industry leaders and scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.

Forward Looking Statements

This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases, cancer and neurological disorders, including TVGN 489 for the treatment of COVID-19 and Long COVID; Tevogen’s ability to develop additional product candidates, including through use of Tevogen’s ExacTcell platform; the anticipated benefits of ExacTcell; expectations regarding Tevogen’s future clinical trials; and Tevogen’s ability to generate revenue in the future. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.

Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the effect of the recent business combination with Semper Paratus Acquisition Corporation (the “Business Combination”) on Tevogen’s business relationships, operating results, and business generally; the outcome of any legal proceedings that may be instituted against Tevogen related to the Business Combination; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; the failure to achieve Tevogen’s commercialization and development plans, and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, and approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Contacts

Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com

FAQ

What is Tevogen Bio's new treatment TVGN 920 targeting?

TVGN 920 is targeting Human Papilloma Virus (HPV), specifically developing a cytotoxic T cell treatment using Tevogen's ExacTcell™ technology.

How is Microsoft helping Tevogen Bio with TVGN 920 development?

Microsoft is providing AI and cloud technologies to help Tevogen Bio accelerate target identification and pre-clinical processes for HPV treatment development.

What is the market size for Tevogen Bio's HPV treatment TVGN 920?

The potential market includes 5.5 million women annually affected by HPV 16/18, with 200,000 women diagnosed with high-grade dysplasia each year.

What technology is Tevogen Bio using for TVGN 920 development?

Tevogen Bio is using its proprietary ExacTcell™ technology, which trains cytotoxic T cells to detect specific targets and has previously shown success with SARS-CoV-2.